Novo Nordisk's pricing approaches inside the U.S. have drawn sharp criticism from lawmakers like Senator Sanders, who's got accused the company of price gouging, stating the stark contrast involving U.S. prices and those in Europe and copyright. California biotech behemoth Amgen ditch